^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1284P - MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer

Published date:
09/14/2020
Excerpt:
In Ph 2, stage IIIB/IV NSCLC pts...Efficacy and safety are reported for pretreated pts with EGFR TKI resistance, with any T790M/MET (Group 1) and treatment (tx)-naive pts with T790M-, any MET (Group 3)....In MET+ pretreated pts, capmatinib plus nazartinib demonstrated clinically relevant efficacy and confirms the role of selective MET inhibition in this subset of post-EGFR TKI pts. Capmatinib plus nazartinib was well tolerated, with similar safety profile across the groups.
Trial ID: